Facilitators and Barriers to Cancer Treatment Among Texas Residents

NCT ID: NCT07105046

Last Updated: 2025-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial uses semi-structured interviews and focus groups to determine facilitators and barriers of receiving timely cancer treatment among multiple cancers, across multiple insurance types, throughout Texas

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objectives:

Aim 1: To comprehensively assess barriers to and facilitators of receiving timely cancer treatment, via in-depth telephone interviews among a purposive sample of Texas patients with Stage I-IV breast, colorectal, lung, and prostate cancer and diverse backgrounds.

Aim 2: To generate consensus on barriers and facilitators, as well as their relative importance, via focus groups, among carefully selected Texas patients with Stage I-IV breast, colorectal, lung and prostate cancer and diverse backgrounds,

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Semi-structured Interview

Participants will be recruited through the Texas Cancer Registry (TCR).

Group Type EXPERIMENTAL

Focus Groups

Intervention Type OTHER

45 to 60 minutes video conference

Online Focus Group

Participants will be recruited through the Texas Cancer Registry (TCR).

Group Type EXPERIMENTAL

Interviews

Intervention Type OTHER

A 30 to 45-minute in-depth semi-structured interview by phone will be administer, following a semi-structured interview guide.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interviews

A 30 to 45-minute in-depth semi-structured interview by phone will be administer, following a semi-structured interview guide.

Intervention Type OTHER

Focus Groups

45 to 60 minutes video conference

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Aims 1 and 2

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

* Verbal consent will be obtained
* Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
* Males and females; Age ≥ 18 years old
* Documented diagnosis of breast, colorectal, lung, and prostate cancer patients, stage I-IV
* Either English or Spanish-speaking

Exclusion Criteria

Aims 1 and 2

An individual who meets any of the following criteria will be excluded from participation in this study:

* Patients who are cognitively impaired
* Pregnant women
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

M.D. Anderson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Lin, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

John Lin, MD

Role: CONTACT

(832) 729-0382

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

John Lin, MD

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mdanderson.org

MD Anderson Cancer Center Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2025-05584

Identifier Type: OTHER

Identifier Source: secondary_id

2025-0697

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ACT-Together (Acting on Cancer Testing-Together)
NCT06549153 ACTIVE_NOT_RECRUITING NA